BR112014015568A2 - compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia - Google Patents

compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia

Info

Publication number
BR112014015568A2
BR112014015568A2 BR112014015568A BR112014015568A BR112014015568A2 BR 112014015568 A2 BR112014015568 A2 BR 112014015568A2 BR 112014015568 A BR112014015568 A BR 112014015568A BR 112014015568 A BR112014015568 A BR 112014015568A BR 112014015568 A2 BR112014015568 A2 BR 112014015568A2
Authority
BR
Brazil
Prior art keywords
epilepsy
prevention
treatment
phenyl carbamate
carbamate compounds
Prior art date
Application number
BR112014015568A
Other languages
English (en)
Other versions
BR112014015568A8 (pt
BR112014015568B1 (pt
Inventor
Moon Choi Yong
Original Assignee
Bio Pharm Solutions Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Pharm Solutions Co Ltd filed Critical Bio Pharm Solutions Co Ltd
Publication of BR112014015568A2 publication Critical patent/BR112014015568A2/pt
Publication of BR112014015568A8 publication Critical patent/BR112014015568A8/pt
Publication of BR112014015568B1 publication Critical patent/BR112014015568B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/02—Carbamic acids; Salts of carbamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/26—Polyhydroxylic alcohols containing only six-membered aromatic rings as cyclic part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/36—Polyhydroxylic alcohols containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

resumo patente de invenção: "compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia". a presente invenção refere-se a um composto carbamato de fenila, uma composição farmacêutica para prevenção e/ou tratamento de epilepsia compreendendo o composto carbamato de fenila como um ingrediente ativo, e uso do composto carbamato de fenila para prevenção e/ou tratamento de epilepsia.
BR112014015568-2A 2011-12-27 2012-12-26 Compostos carbamato de fenila, composição farmacêutica, e seus usos na prevenção ou tratamento de epilepsia BR112014015568B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161580409P 2011-12-27 2011-12-27
US61/580,409 2011-12-27
PCT/KR2012/011474 WO2013100570A1 (en) 2011-12-27 2012-12-26 Phenyl carbamate compounds for use in preventing or treating epilesy

Publications (3)

Publication Number Publication Date
BR112014015568A2 true BR112014015568A2 (pt) 2017-06-13
BR112014015568A8 BR112014015568A8 (pt) 2017-07-04
BR112014015568B1 BR112014015568B1 (pt) 2022-03-29

Family

ID=48655156

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112014015482A BR112014015482A8 (pt) 2011-12-27 2012-12-26 compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
BR112014015568-2A BR112014015568B1 (pt) 2011-12-27 2012-12-26 Compostos carbamato de fenila, composição farmacêutica, e seus usos na prevenção ou tratamento de epilepsia

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112014015482A BR112014015482A8 (pt) 2011-12-27 2012-12-26 compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática

Country Status (13)

Country Link
US (6) US20130184338A1 (pt)
EP (6) EP2797878B1 (pt)
JP (8) JP6089045B2 (pt)
KR (6) KR20140113919A (pt)
CN (6) CN104870421A (pt)
AU (2) AU2012360365B2 (pt)
BR (2) BR112014015482A8 (pt)
CA (2) CA2858977C (pt)
ES (3) ES2716832T3 (pt)
IN (2) IN2014MN01432A (pt)
MX (2) MX353024B (pt)
RU (2) RU2014124029A (pt)
WO (6) WO2013100571A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
CN104870421A (zh) 2011-12-27 2015-08-26 比皮艾思药物研发有限公司 用于预防或治疗als的苯基氨基甲酸酯化合物
KR101717872B1 (ko) 2013-03-12 2017-03-17 (주)바이오팜솔루션즈 소아 간질 및 간질-관련 증후군의 예방 또는 치료용 페닐카바메이트 화합물
KR101758543B1 (ko) * 2013-03-12 2017-07-14 (주)바이오팜솔루션즈 페닐카바메이트 화합물 및 이를 포함하는 신경가스에 의한 질환의 예방 또는 치료용 조성물
EP3443959A1 (en) * 2013-12-12 2019-02-20 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds for use in treating or alleviating pain
ES2706184T3 (es) * 2013-12-12 2019-03-27 Bio Pharm Solutions Co Ltd Compuesto derivado de sulfamato para su uso en la prevención o el tratamiento de la epilepsia
CA3016253C (en) * 2016-02-29 2020-12-29 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds, processes for preparing them and their uses
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
KR102005019B1 (ko) 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
US20210361318A1 (en) 2018-07-02 2021-11-25 Voyager Therapeutics, Inc. Cannula system and use thereof
WO2020010042A1 (en) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
KR102427769B1 (ko) 2020-08-07 2022-08-02 한국과학기술연구원 다발성 경화증 예방 또는 치료용 조성물
KR102531540B1 (ko) 2020-09-18 2023-05-16 한국과학기술연구원 류마티스 관절염 예방 또는 치료용 조성물
KR102614653B1 (ko) 2021-06-09 2023-12-20 한국과학기술연구원 신규한 헤테로사이클릴-페닐-메틸아민 유도체, 이의 제조방법 및 이의 다발성 경화증 예방, 개선, 또는 치료 용도
WO2023014160A1 (ko) 2021-08-05 2023-02-09 (주)바이오팜솔루션즈 페닐카바메이트 결정형 및 이의 제조 방법
KR102399807B1 (ko) 2021-08-05 2022-05-20 (주)바이오팜솔루션즈 페닐카바메이트 결정형 및 이의 제조 방법

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2884444A (en) 1956-01-13 1959-04-28 Carter Prod Inc 2-phenyl-1,3 propane diol dicarbamate
US2937119A (en) 1959-06-11 1960-05-17 Carter Prod Inc Nu-monosubstituted-2, 2-dialkyl-1, 3-propanediol dicarbamates
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265727A (en) 1962-06-26 1966-08-09 Armour Pharma Phenyl alkyl-1, 2 dicarbamates
US3313696A (en) * 1962-06-26 1967-04-11 Armour Pharmacentical Company Carbamate sedative compositions and method of use
US3313699A (en) * 1962-06-26 1967-04-11 Armour Pharma Compositions for and method of treating the central nervous system
US3313700A (en) * 1962-07-18 1967-04-11 Armour Pharmacentical Company Method of treating the central nervous system with substituted phenethyl carbamates and compositions therefor
US3265728A (en) 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
FR5671M (pt) * 1965-04-23 1968-01-02
US3600427A (en) 1967-05-08 1971-08-17 Anthony J Verbiscar Phenyl carbamate latentiated phenethylamines
JPS61271992A (ja) * 1985-05-28 1986-12-02 Central Glass Co Ltd 光学活性ジオ−ルの製造方法
WO1994027941A1 (en) * 1993-05-25 1994-12-08 Avondale Chemical Company Process for preparing felbamate and intermediates thereto
US20010034365A1 (en) * 1996-01-16 2001-10-25 Choi Yong Moon Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US6242468B1 (en) * 1997-02-27 2001-06-05 Jia-He Li Carbamate and urea compositions and neurotrophic uses
JP3960801B2 (ja) * 1999-11-29 2007-08-15 三菱レイヨン株式会社 アセタールスルホネート誘導体およびその製造方法ならびにスチレンオキサイド誘導体の製造方法
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
DK1404312T3 (da) * 2001-02-27 2011-03-14 Ortho Mcneil Pharm Inc Carbamatforbindelser til anvendelse ved smertebehandling
CN1235579C (zh) * 2001-02-27 2006-01-11 奥索-麦克尼尔药品公司 用于预防或治疗神经变性疾病的氨基甲酸酯化合物
ES2261655T3 (es) 2001-04-02 2006-11-16 Astrazeneca Ab Composicion farmaceutica solida que comprende 4'-ciano-trifluoro-3-(4-fluorofenilsulfonil)-2-hidroxi-2-metilpropiono-m-toluiduro y pvp.
CN100338055C (zh) 2001-06-25 2007-09-19 Sk株式会社 2－杂环－1,2－乙二醇的氨基甲酸酯
PT1408954E (pt) * 2001-07-16 2009-07-28 Ortho Mcneil Janssen Pharm Compostos carbamatos para utilização na prevenção ou tratamento da dor neuropática
KR20090097966A (ko) * 2001-12-21 2009-09-16 오르토-맥네일 파마슈티칼, 인코퍼레이티드 2-(치환된 페닐)-2-하이드록시-에틸 카바메이트의 제조방법
FR2836915B1 (fr) * 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
WO2003101917A2 (en) 2002-05-31 2003-12-11 Sun Pharmaceutical Industries Limited A process for the preparation of phenylcarbamates
BRPI0409787B8 (pt) * 2003-04-23 2021-05-25 Merck Sharp & Dohme antagonistas receptores da 2-alquinil- e 2-alquenil-pirazol-[4,3-e]-1,2,4-triazol-[1,5-c]-pirimidina adenosina a2a
AU2004287495A1 (en) 2003-11-05 2005-05-19 Unimed Pharmaceuticals, Inc. Delta-9- the treatment of multiple sclerosis
ES2342082T3 (es) * 2004-04-21 2010-07-01 Schering Corporation Antagonistas de receptores a2a de adenosina de pirazolo(4,3-e)-1,2,4-triazolo(1,5-c)pirimidina.
JP5001150B2 (ja) * 2004-06-08 2012-08-15 ファミリーズ オブ スパイナル マスキュラー アトロフィー 脊髄性筋萎縮症のための２，４−ジアミノキナゾリン
US20060194873A1 (en) * 2004-09-16 2006-08-31 Choi Yong M Methods of treating epileptogenesis and epilepsy
CN101076327A (zh) * 2004-10-15 2007-11-21 詹森药业有限公司 用于治疗神经变性疾病的氨基甲酸酯化合物
US7442438B2 (en) 2005-05-04 2008-10-28 3M Innovative Properties Company Wet and dry stick adhesive, articles, and methods
TW200800954A (en) 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
ZA200900161B (en) * 2006-07-28 2010-05-26 Eisai R&D Man Co Ltd Prodrug of cinnamide compound
SA07280403B1 (ar) * 2006-07-28 2010-12-01 إيساي أر أند دي منجمنت كو. ليمتد ملح رباعي لمركب سيناميد
KR20090076958A (ko) * 2006-10-06 2009-07-13 얀센 파마슈티카 엔.브이. 신규 (ｓ)-(＋)-2-(2-클로로페닐)-2-하이드록시-에틸 카바메이트 결정
CN101663026A (zh) 2006-10-13 2010-03-03 詹森药业有限公司 氨基甲酸苯基烷基酯组合物
MX2009004553A (es) 2006-10-27 2009-11-10 Janssen Pharmaceutica Nv Metodos para el tratamiento de trastornos cocleares y vestibulares.
MX2009004770A (es) 2006-10-30 2009-08-17 Janssen Pharmaceutica Nv Compuestos de carbamato para usarse en el tratamiento de la depresion.
PE20081775A1 (es) * 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
MX2009010984A (es) 2007-04-10 2010-01-15 Sgx Pharmaceuticals Inc Moduladores de heterociclo cinasa de anillo fusionado.
WO2009022345A1 (en) 2007-08-14 2009-02-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Phenyl carbamates for the treatment of multiple sclerosis
US20090105498A1 (en) * 2007-10-18 2009-04-23 Porstmann Frank Improved process for preparing 2-(substituted phenyol)-2-hydroxy-ethyl-carbamates
CN102159077A (zh) 2008-08-21 2011-08-17 吉瑞工厂 用于治疗神经性疼痛的方法
JP2011219387A (ja) * 2010-04-06 2011-11-04 Kaneka Corp イオン液体の製造方法
CN103080079B (zh) * 2010-07-02 2015-01-21 比皮艾思药物研发有限公司 苯基氨基甲酸酯化合物及含有苯基氨基甲酸酯化合物的肌肉松弛剂
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
CA2815460C (en) 2011-01-13 2017-04-18 Bio-Pharm Solutions Co., Ltd. Process for preparation of phenyl carbamate derivatives
BR112013021896A2 (pt) * 2011-02-28 2016-11-08 Array Biopharma Inc inibidores de serina/treonina cinase
CN104870421A (zh) 2011-12-27 2015-08-26 比皮艾思药物研发有限公司 用于预防或治疗als的苯基氨基甲酸酯化合物

Also Published As

Publication number Publication date
RU2632659C2 (ru) 2017-10-09
EP2797877A1 (en) 2014-11-05
US20130184338A1 (en) 2013-07-18
US9624164B2 (en) 2017-04-18
EP2797880A1 (en) 2014-11-05
US20130165509A1 (en) 2013-06-27
US20130203846A1 (en) 2013-08-08
CN104136415B (zh) 2016-09-07
KR101795562B1 (ko) 2017-11-08
MX2014008021A (es) 2014-08-01
CN104169253A (zh) 2014-11-26
WO2013100567A1 (en) 2013-07-04
KR20140113918A (ko) 2014-09-25
EP2797881A1 (en) 2014-11-05
JP2015506934A (ja) 2015-03-05
US9034848B2 (en) 2015-05-19
EP2797879A1 (en) 2014-11-05
BR112014015482A8 (pt) 2017-07-04
AU2012360365A1 (en) 2014-08-07
MX2014008020A (es) 2014-12-08
ES2624989T3 (es) 2017-07-18
JP2015508398A (ja) 2015-03-19
CN104169253B (zh) 2016-11-09
KR20140108245A (ko) 2014-09-05
JP2018108996A (ja) 2018-07-12
IN2014MN01432A (pt) 2015-07-03
US20130165409A1 (en) 2013-06-27
US20130165410A1 (en) 2013-06-27
WO2013100567A8 (en) 2014-02-20
WO2013100568A1 (en) 2013-07-04
CN104870421A (zh) 2015-08-26
KR20140113914A (ko) 2014-09-25
RU2014124028A (ru) 2016-02-20
JP6155280B2 (ja) 2017-06-28
CA2859129A1 (en) 2013-07-04
EP2797879A4 (en) 2015-10-07
AU2012360362B2 (en) 2017-08-31
JP2015504055A (ja) 2015-02-05
WO2013100571A9 (en) 2014-09-18
JP6298765B2 (ja) 2018-03-20
MX353024B (es) 2017-12-18
CA2859129C (en) 2020-07-14
EP2797879B1 (en) 2018-12-26
JP6298766B2 (ja) 2018-03-20
EP2797878A1 (en) 2014-11-05
JP2015503550A (ja) 2015-02-02
WO2013100569A1 (en) 2013-07-04
CA2858977A1 (en) 2013-07-04
EP2797881A4 (en) 2016-01-13
CN104136416B (zh) 2016-11-09
AU2012360365B2 (en) 2017-08-31
IN2014MN01436A (pt) 2015-07-03
EP2797877A4 (en) 2015-10-07
CA2858977C (en) 2020-06-23
EP2797876A1 (en) 2014-11-05
KR101862203B1 (ko) 2018-05-29
WO2013100570A1 (en) 2013-07-04
JP2015504054A (ja) 2015-02-05
WO2013100566A1 (en) 2013-07-04
ES2710902T3 (es) 2019-04-29
BR112014015568A8 (pt) 2017-07-04
EP2797878A4 (en) 2015-10-07
RU2014124029A (ru) 2016-02-20
ES2716832T3 (es) 2019-06-17
KR20140113919A (ko) 2014-09-25
CN104136413A (zh) 2014-11-05
JP2017193577A (ja) 2017-10-26
EP2797876A4 (en) 2015-10-07
BR112014015482A2 (pt) 2017-06-13
EP2797878B1 (en) 2017-08-16
US9162975B2 (en) 2015-10-20
CN104136414A (zh) 2014-11-05
EP2797880A4 (en) 2015-10-07
CN104136416A (zh) 2014-11-05
WO2013100566A8 (en) 2014-02-20
KR20140108226A (ko) 2014-09-05
KR101795563B1 (ko) 2017-11-08
US20130165408A1 (en) 2013-06-27
KR101880584B1 (ko) 2018-07-20
JP6089045B2 (ja) 2017-03-01
EP2797880B1 (en) 2017-03-01
BR112014015568B1 (pt) 2022-03-29
AU2012360362A1 (en) 2014-08-07
US9029589B2 (en) 2015-05-12
WO2013100571A1 (en) 2013-07-04
KR20150023217A (ko) 2015-03-05
MX338554B (es) 2016-04-20
CN104136413B (zh) 2016-10-26
JP2015504053A (ja) 2015-02-05
CN104136415A (zh) 2014-11-05
EP2797881B1 (en) 2018-11-14

Similar Documents

Publication Publication Date Title
BR112014015568A8 (pt) compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia
DK201470535A (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
IN2014CN02128A (pt)
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
EA201500448A1 (ru) Гуанидиновое соединение
EA201290919A1 (ru) Индазольные соединения и их применение
EA201390885A1 (ru) Азаиндолы в качестве противовирусных агентов против респираторного синцитиального вируса
EA201692506A3 (ru) Ингибиторы репликации вирусов гриппа
EA201390339A1 (ru) Замещенные имидазопиридазины
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
CL2013001482A1 (es) Compuestos derivados de 3-metil-7-oxo-4-tia-1-aza-biciclo[3.2.0]heptano para utilizarse en la inhibicion de beta-lactamasas producidas por bacterias y restaurar/potenciar la actividad de antibioticos; y composicion farmaceutica que los comprende.
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
EP2886112A4 (en) COMPOSITION CONTAINING AS ACTIVE INGREDIENT OF S-ALLYL-L-CYSTEINE FOR PREVENTING OR TREATING OCULAR DISEASES, AND PHARMACEUTICAL FORMULATION COMPRISING THE SAME
WO2013038200A3 (en) Neurodevelopmental disorders
WO2013049280A3 (en) Sphingosine analogs, compositions, and methods related thereto
WO2014172453A3 (en) Novel compositions useful in treating brain-related diseases or disorders and methods using same
BR112015028884A2 (pt) tratamento ou prevenção de depressão utilizando mentol e/ou icilina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/12/2012, OBSERVADAS AS CONDICOES LEGAIS.